CoChat
Cited by 479

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure

McAlister, Finlay A., Wiebe, Natasha, Ezekowitz, Justin A., Leung, Alexander A., Armstrong, Paul W. · 2009 · Annals of Internal Medicine

Abstract

BACKGROUND: Guidelines recommend that patients with heart failure receive beta-blockers in doses used in the trials that have proven their efficacy. Although the adverse effects of beta-blockade are dose-related, it is unclear whether the benefits are. PURPOSE: To determine whether the survival benefits of beta-blockade in heart failure are associated with the magnitude of heart rate reduction or the beta-blocker dose. DATA SOURCES: MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science, and the Cochrane Central Register of Controlled Trials, supplemented by hand-searches of bibliographies. STUDY SELECTION: Randomized, placebo-controlled heart failure trials that reported all-cause mortality. DATA EXTRACTION: Two reviewers independently extracted data on study characteristics, beta-blocker dosing and heart rate reduction, and death. DATA SYNTHESIS: The mean left ventricular ejection fraction in the 23 beta-blocker trials ranged from 0.17 to 0.36, and more than 95% of the 19 209 patients had systolic dysfunction. The overall risk ratio for death was 0.76 (95% CI, 0.68 to 0.84); however, heterogeneity testing revealed moderate heterogeneity among trials (I (2) = 30%), which was associated with the magnitude of heart rate reduction achieved within each trial (P for meta-regression = 0.006). For every heart rate reduction of 5 beats/min with beta-blocker treatment, a commensurate 18% reduction (CI, 6% to 29%) in the risk for death occurred. No significant relationship between all-cause mortality and beta-blocker dosing was observed (risk ratio for death, 0.74 [CI, 0.64 to 0.86]) in high-dose beta-blocker trials vs. 0.78 [CI, 0.63 to 0.96] in low-dose beta-blocker trials; P for meta-regression = 0.69). LIMITATIONS: The analysis is based on aggregate data and resting heart rates. Few patients in these trials had bradycardia or diastolic dysfunction at baseline. CONCLUSION: The magnitude of heart rate reduction is statistically significantly associated with the survival benefit of beta-blockers in heart failure, whereas the dose of beta-blocker is not.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-150-11-200906020-00006

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 3

  1. 10.1093/eurheartj/sum031 · DOI
  2. 10.1088/0031-9155/21/2/001 · doi:10.1088/0031-9155/21/2/001
  3. 10.1093/eurheartj/ehi386 · DOI · Paper page

Cited by

See all 479

Metadata

Authors
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W.
Venue
Annals of Internal Medicine
Published
2009-06-02
Volume
150
Issue
11
Pages
784-794
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1985431801
Cited by
479
References
54
FWCI
19.18
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. https://app.cochat.ai/papers/10.7326/0003-4819-150-11-200906020-00006
The paper
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009). Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-150-11-200906020-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.